Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$4.54 -1.9%	$5.28	$1.38 ▼ $7.34	$144.66M	1.62	812,762 shs	245,771 shs
FBIO Fortress Biotech	$2.34 -0.4%	$1.94	$1.33 ▼ $2.49	$69.62M	1.76	280,423 shs	499,009 shs
IRWD Ironwood Pharmaceuticals	$1.26 -0.8%	$0.85	$0.53 ▼ $5.21	$204.66M	0.33	2.81 million shs	415,610 shs
SGMO Sangamo Therapeutics	$0.54 -0.3%	$0.53	$0.41 ▼ $3.18	$162.44M	1.18	6.07 million shs	2.31 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	+5.47%	+2.21%	-22.32%	+53.31%	-21.12%
FBIO Fortress Biotech	+2.62%	+7.31%	+19.29%	+23.68%	+9.30%
IRWD Ironwood Pharmaceuticals	0.00%	+18.69%	+55.58%	+114.38%	-74.80%
SGMO Sangamo Therapeutics	-1.82%	-3.66%	-7.79%	+19.44%	-33.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGEN Agenus	3.9053 of 5 stars	3.3	2.0	4.6	1.9	1.7	0.6
FBIO Fortress Biotech	2.8062 of 5 stars	3.5	1.0	0.0	3.1	3.3	0.6
IRWD Ironwood Pharmaceuticals	4.5994 of 5 stars	3.1	5.0	3.4	3.8	0.8	1.9
SGMO Sangamo Therapeutics	2.5818 of 5 stars	3.3	4.0	0.0	2.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGEN Agenus	2.50	Moderate Buy	$15.50	241.41% Upside
FBIO Fortress Biotech	3.00	Buy	$16.50	605.13% Upside
IRWD Ironwood Pharmaceuticals	2.14	Hold	$4.94	292.06% Upside
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$4.50	735.81% Upside

Current Analyst Ratings Breakdown

Latest FBIO, SGMO, IRWD, and AGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	FBIO Fortress Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
8/12/2025	AGEN Agenus	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	SGMO Sangamo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/4/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$4.00 ➝ $6.00
6/4/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGEN Agenus	$101.71M	1.42	N/A	N/A	($10.55) per share	-0.43
FBIO Fortress Biotech	$57.67M	1.21	N/A	N/A	$1.26 per share	1.86
IRWD Ironwood Pharmaceuticals	$351.41M	0.58	$0.05 per share	25.68	($1.90) per share	-0.66
SGMO Sangamo Therapeutics	$57.80M	2.81	N/A	N/A	$0.06 per share	8.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGEN Agenus	-$227.21M	-$7.15	N/A	N/A	N/A	-167.52%	N/A	-81.04%	11/11/2025 (Estimated)
FBIO Fortress Biotech	-$46M	-$1.05	N/A	N/A	N/A	-24.84%	-301.81%	-27.48%	11/13/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	$880K	-$0.05	N/A	5.04	N/A	-2.25%	-2.46%	2.19%	11/6/2025 (Estimated)
SGMO Sangamo Therapeutics	-$97.94M	-$0.29	N/A	N/A	N/A	-77.48%	-293.05%	-63.85%	11/11/2025 (Estimated)

Latest FBIO, SGMO, IRWD, and AGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FBIO Fortress Biotech	-$0.31	-$0.46	-$0.15	$0.45	$14.53 million	$16.41 million
8/11/2025	Q2 2025	AGEN Agenus	-$0.78	-$1.00	-$0.22	-$1.00	$49.71 million	$25.70 million
8/7/2025	Q2 2025	IRWD Ironwood Pharmaceuticals	-$0.02	$0.14	+$0.16	$0.14	$62.02 million	$85.24 million
8/7/2025	Q2 2025	SGMO Sangamo Therapeutics	-$0.07	-$0.08	-$0.01	-$0.08	$31.68 million	$18.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGEN Agenus	N/A	0.06	0.06
FBIO Fortress Biotech	1.34	1.92	1.70
IRWD Ironwood Pharmaceuticals	N/A	0.82	0.82
SGMO Sangamo Therapeutics	N/A	1.05	1.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGEN Agenus	61.46%
FBIO Fortress Biotech	96.51%
IRWD Ironwood Pharmaceuticals	N/A
SGMO Sangamo Therapeutics	56.93%

Insider Ownership

Company	Insider Ownership
AGEN Agenus	5.50%
FBIO Fortress Biotech	27.90%
IRWD Ironwood Pharmaceuticals	12.70%
SGMO Sangamo Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGEN Agenus	440	31.86 million	30.11 million	Optionable
FBIO Fortress Biotech	170	29.75 million	21.45 million	Optionable
IRWD Ironwood Pharmaceuticals	220	162.43 million	141.81 million	Optionable
SGMO Sangamo Therapeutics	480	301.71 million	289.34 million	Optionable

FBIO, SGMO, IRWD, and AGEN Headlines

Recent News About These Companies

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Down 41.5% in July

August 20, 2025 | marketbeat.com

Sangamo Therapeutics (NASDAQ:SGMO) Raised to "Hold" at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Q3 EPS Forecast for Sangamo Therapeutics Boosted by Analyst

August 17, 2025 | marketbeat.com

Wall Street Zen Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to "Hold"

August 17, 2025 | marketbeat.com

Analysts Issue Forecasts for SGMO Q4 Earnings

August 16, 2025 | marketbeat.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.50 Consensus PT from Brokerages

August 16, 2025 | americanbankingnews.com

HC Wainwright Analysts Raise Earnings Estimates for SGMO

August 16, 2025 | americanbankingnews.com

What Makes Sangamo (SGMO) a New Buy Stock

August 14, 2025 | zacks.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of "Moderate Buy" from Brokerages

August 14, 2025 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Zimmer Biomet Holdings (ZBH)

August 9, 2025 | theglobeandmail.com

Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

GSA Capital Partners LLP Boosts Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

August 4, 2025 | marketbeat.com

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

July 31, 2025 | globenewswire.com

Sangamo Therapeutics (SGMO) Expected to Announce Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy

July 25, 2025 | msn.com

H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data

July 3, 2025 | msn.com

SGMO - Sangamo Therapeutics Inc Trailing Returns - Morningstar

July 2, 2025 | morningstar.comM

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Morningstar

June 25, 2025 | morningstar.comM

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire

June 25, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, SGMO, IRWD, and AGEN Company Descriptions

Agenus NASDAQ:AGEN

$4.54 -0.09 (-1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$4.54 +0.00 (+0.11%)

As of 05:35 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Fortress Biotech NASDAQ:FBIO

$2.34 -0.01 (-0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$2.37 +0.03 (+1.07%)

As of 05:50 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Ironwood Pharmaceuticals NASDAQ:IRWD

$1.26 -0.01 (-0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$1.27 +0.01 (+0.79%)

As of 05:47 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Sangamo Therapeutics NASDAQ:SGMO

$0.54 0.00 (-0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$0.54 +0.00 (+0.67%)

As of 05:51 PM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time